Inhibition of NF-κB activation reduced cisplatin nephrotoxicity without affecting its oncolytic action [48, 49], which might be explained by the observation that cisplatin nephrotoxicity was mediated via TNFR2, whereas the anti-tumor effect of TNF-α was mediated by TNFR1. This evidence concerns the gene NFKB1 and neoplasm.